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dent risk factor for death in groups A and B, but not in group 
C [group A: hazard ratio (HR) 1.42, 95% confidence interval 
(CI) 1.10–1.81; group B: HR 1.29, 95% CI 1.00–1.67; group C: HR 
1.05, 95% CI 0.78–1.43].  Conclusion:  The prevalence of AF in-
creased with age and was associated with a higher mortality 
rate. However, AF independently predicted all-cause mortal-
ity only in patients aged  ^  75 years.
 Copyright © 2010 S. Karger AG, Basel
 Introduction
 Atrial fibrillation (AF) is the most common cardiac 
arrhythmia in patients living in industrialized countries 
 [1] , and heart failure (HF) has to be considered the preva-
lent cardiovascular disease in the 21st century  [2] . Both 
diseases are frequently diagnosed in the elderly, in whom 
they often coexist because one predisposes the patient to 
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 Abstract
 Objectives: The role of atrial fibrillation (AF) in older patients 
with heart failure (HF) is controversial because many vari-
ables seem to influence their outcome. We investigated the 
predictivity of AF in 3 age groups of outpatients with HF. 
 Methods: We analyzed 8,178 outpatients enrolled in the Ital-
ian Network on Congestive Heart Failure Registry with HF 
diagnosed according to the European Society of Cardiology 
criteria. A trained cardiologist established the diagnosis of 
AF and HF at the entry visit at each center. We stratified the 
population into 3 age groups, as follows: group A,  ^  65 years; 
group B, 66–75 years, and group C,  1 75 years.  Results: Group 
A was composed of 4,261 patients, 683 with AF (16.0%); in 
group B there were 2,651 patients, 638 with AF (24.1%), and 
group C was composed of 1,266 patients, 412 with AF (32.5%). 
The 1-year mortality rate was higher in AF patients in all 
groups. In a multivariate model, AF remained an indepen-
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the other  [3–5] . This frequent association markedly wors-
ens symptoms and increases morbidity and hospitaliza-
tions in older patients, with an elevated cost for health 
care services  [6] . The pathophysiological correlations be-
tween these two cardiac disorders have already been clar-
ified  [7–9] and are partially related to the same risk fac-
tors as those relevant for ischemic heart disease and hy-
pertension  [8, 9] or the same precipitating factors (e.g. 
pulmonary infections or decompensated chronic ob-
structive pulmonary disease)  [10, 11] . Alteration of sym-
pathetic activation, neurohormonal pathway overexpres-
sion and enlargement of the heart chambers  [12, 13] are 
some of the pathophysiological mechanisms that link 
these two disorders and that are responsible for their pro-
gressive clinical deterioration. The hemodynamic and 
clinical consequences of the presence of AF in patients 
with HF are well known and are correlated with the lack 
of atrial synchrony and contribution to left ventricular 
filling, irregular ventricular rate, increase in mean dia-
stolic pressure in the atria and decrease in the cardiac 
index  [12, 14] . Negative hemodynamic effects of AF are 
highly deleterious in older patients because atrial contri-
bution to the diastolic filling volume is greater than in 
younger patients  [15] .
 On the basis of these hemodynamic and clinical find-
ings, many studies have attempted to clarify the prognos-
tic role of AF in patients with HF, but the data are quite 
conflicting, sometimes also for the same authors  [9] .
 The aim of the present study was to verify the prog-
nostic role of AF in different age groups of patients with 
HF enrolled in the Italian Network on Congestive Heart 
Failure Registry  [16] .
 Methods
 Study Design, Collected Data and Definitions
 Data for the present analysis originate from the database of the 
Italian Network on Congestive Heart Failure Registry  [16] , a per-
manent registry designed by an ad hoc committee of the Italian 
Association of Hospital Cardiologists (Associazione Nazionale 
Medici Cardiologi Ospedalieri, Florence, Italy) in 1995. 150 car-
diology centers actively participated in the study, which was a 
good representation of the cardiology centers existing in our 
country. Short training sessions were organized to prepare clini-
cians to collect and enter data into the registry. Using an ad hoc 
designed software, patients’ data were recorded at each center by 
trained cardiologists and were then pooled into a database at the 
Italian Association of Hospital Cardiologists Research Center. A 
requirement for entry into the database was that patients had a 
diagnosis of HF based on the European Society of Cardiology 
guideline criteria  [17] . Data on demographic, clinical, instrumen-
tal and biohumoral variables and therapies were collected for each 
patient. At baseline, a 12-lead ECG was recorded and coded by a 
single cardiologist at each participating center, using a standard-
ized format outlined in the database. Patients were followed ac-
cording to the routine clinical practice of the participating cen-
ters. In this context, patients underwent standard chest X-ray, 24-
hour Holter ECG monitoring to confirm the presence of persistent 
or permanent AF, two-dimensional echocardiography and blood 
sampling for the most common laboratory tests, and others if the 
attending cardiologists deemed them necessary. Cardiologists at 
the participating centers were responsible for confirming the di-
agnosis of AF and classifying it as persistent or permanent, for 
defining the etiology of congestive HF and the NYHA class, re-
porting whether a third heart sound was audible and computing 
the cardiothoracic ratio. Left ventricular ejection fraction was cal-
culated from a 4-chamber apical echocardiographic view. Ven-
tricular tachycardia was defined as an episode of tachycardia with 
widened QRS that lasted longer than 3 beats with a heart rate  1 100 
beats/min, as revealed by 24-hour Holter ECG monitoring. Renal 
insufficiency was defined as serum creatinine  1 2.5 mg/dl, hypo-
kalemia as a serum potassium value  ! 3.5 mEq/l and anemia as 
hemoglobin  ! 11 mg/dl for women and  ! 12 mg/dl for men. Previ-
ous hospitalizations for congestive HF in the year before the entry 
visit were also recorded. After the baseline visit, patients were fol-
lowed up for at least 1 year. In the case of death occurring outside 
the hospital, the event was confirmed by a telephone interview 
with the patient’s relatives, using a standard questionnaire aimed 
at determining the type of death (sudden vs. nonsudden).
 Study Population
 A total of 8,178 consecutive patients with HF were followed for 
1 year, and available data on AF were considered for the present 
analysis, excluding patients on a waiting list for heart transplanta-
tion. Patients were stratified into 3 age groups as follows: group 
A,  ^  65 years; group B, 66–75 years, and group C,  1 75 years.
 Statistical Analyses
 Continuous variables are reported as means  8 standard de-
viation and compared by t test, while categorical variables are re-
ported as percentages and compared by   2  test. Patients with AF 
were compared to patients without AF in each of the 3 age groups. 
Multivariate analyses (Cox models) were used to determine the 
independent predictors of 1-year all-cause mortality, 1-year sud-
den death and 1-year all-cause hospitalization in each age group. 
Variables statistically significant in univariate analysis and vari-
ables considered of relevant clinical interest, even though not sta-
tistically significant, were used in the models. The following vari-
ables were considered: gender (female vs. male), NYHA class (III–
IV vs. I–II), ischemic etiology, systolic blood pressure (continuous), 
heart rate (continuous), hospitalization for HF in the previous 
year, creatinine ( 1 2.5 vs.  ^  2.5 mg/dl), cardiothoracic ratio ( 1 0.55 
vs.  ^  0.55), ejection fraction ( ^  30 vs.  1 30%), third heart sound, 
AF (yes vs. no) and use of angiotensin-converting enzyme (ACE) 
inhibitors and   -blockers (no vs. yes). Firstly, a Cox model was 
performed for the 3 end-points in the total population of patients, 
introducing age as a continuous variable, in order to evaluate the 
prognostic role of age. Also, Kaplan-Meier curves according to the 
presence or absence of AF were calculated for the above-men-
tioned 3 end-points in each age group and compared by log-rank 
test. A p value  ! 0.05 was considered statistically significant. All 
data were analyzed using SAS  software (version 8.2)  [18] .
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 Results
 Baseline Characteristics
 In  table 1 , the clinical characteristics of the study pop-
ulation compared according to the presence of AF in each 
age group are reported. There were significant differenc-
es in the mean age between patients with AF and those 
without AF in each group. An increasing proportion of 
females among patients with AF was observed moving 
from group A to group C (19.9 vs. 32.5 vs. 50.2%). Ad-
vanced NYHA class (III–IV) was prevalent in patients 
with AF in all 3 groups.
 The etiology of HF differed substantially between pa-
tients with AF and without AF in all 3 groups; dilated 
cardiomyopathy was the most frequent cause of HF in 
group A, while ischemic etiology was more frequent in 
groups B and C. A greater percentage of patients with AF 
had had a previous hospitalization compared with those 
without AF in all age groups.
 As expected, the proportion of HF patients with pre-
served ejection fraction ( 1 40%) increased with increas-
ing age; in all age groups, the proportion of patients with 
AF was higher in the group of patients with preserved 
ejection fraction. Hypokalemia was associated with AF 
in all age groups, although only in group C was there a 
significant difference compared to patients in sinus 
rhythm (4.2 vs. 1.4%; p = 0.03). In contrast, renal insuf-
ficiency was prevalent in patients without AF in all age 
groups, with a significant difference only in group C (5.4 
vs. 1.7%; p = 0.03). Considering the prevalence of other 
electrical disturbances, we found that ventricular tachy-
cardia was more frequent in patients with AF in all 3 
groups, although data on this arrhythmia were available 
only for a relatively small number of patients; the differ-
ence between patients with and without AF was signifi-
cant only in group A (36.0 vs. 27.0%; p = 0.03). Anemia 
progressively increased across the 3 age groups without 
reaching statistical significance in any of them. Left bun-
 Table 1.  Clinical and hemodynamic characteristics in the 3 groups of patients according to the presence or absence of AF
Group A: age ≤65 years 
(n = 4,261)
Group B: age 66–75 years 
(n = 2,651)
G roup C: age >75 years 
(n = 1,266)
AF
(n = 683)
no AF
(n = 3,578)
p AF
(n = 638)
no AF
(n = 2,013)
p AF
(n  = 412)
no AF
(n = 854)
p
Mean  8 SD age, years 57 8 7 54 8 10 <0.0001 71 8 3 70 8 3 0.006 81 8 4 80 8 4 0.010
Females, % 19.9 21.1 0.48 32.5 27.2 0.011 50.2 42.7 0.012
NYHA class III–IV, % 36.6 25.5 <0.0001 42.5 29.3 <0.0001 41.3 34.5 0.020
Etiology of HF, %
Ischemic
 Valvular
 Hypertensive
Idiopathic
Other
17.6
22.1
12.0
39.4
8.9
37.0
6.0
9.1
42.3
5.6
<0.0001
28.1
27.3
16.9
22.9
4.8
52.1
8.1
13.6
23.4
2.8
<0.0001
32.5
20.4
22.6
17.0
7.5
48.8
11.9
20.1
14.9
4.3
<0.0001
Third heart sound, % 20.9 27.6 0.0003 18.0 21.3 0.073 17.5 17.2 0.91
Previous hospitalization, % 59.2 53.9 0.012 63.0 55.5 0.0009 65.8 57.6 0.005
Ejection fraction, % 1 
>40%
30–40%
<30%
26.6
37.2
36.2
21.1
40.1
38.8
0.044
35.0
41.5
23.5
22.7
46.1
31.2
<0.0001
41.4
42.7
15.9
33.5
44.2
22.3
0.047
Potassium <3.5 mEq/l, % 2 2.4 1.6 0.26 3.7 2.0 0.070 4.2 1.4 0.029
Creatinine >2.5 mg/dl, % 3 1.4 2.1 0.37 2.3 3.6 0.22 1.8 5.4 0.026
Ventricular tachycardia, % 4 36.0 27.0 0.029 33.9 30.0 0.43 37.7 30.1 0.33
Anemia, % 5 13.6 12.4 0.54 15.2 15.2 1.00 21.5 26.5 0.22
LBBB, % 17.4 25.1 <0.0001 15.0 25.5 <0.0001 13.8 22.6 0.0002
Cardiothoracic ratio >0.55, % 6 64.3 51.3 0.029 74.4 62.6 0.060 74.5 62.5 0.14
Pre vious hospitalisation was defined as one or more hospitalizations in 
the year prior to entry in the registry. LBBB = left bundle branch block.
 1  4,977 patients with data available (group A = 2,692 patients; group B = 
1,571 patients; group C = 714 patients).  2  4,589 patients with data available 
(group A = 2,481 patients; group B = 1,467 patients; group C = 641 patients). 
 3  4,682 patients with data available (group A = 2,506 patients; group B = 
1,499 patients; group C = 677 patients).  4  1,730 patients with data available 
(group A = 1,039 patients; group B = 525 patients; group C = 166 patients). 
 5  3,557 patients with data available (group A = 1,919 patients; group B = 
1,125 patients; group C = 513 patients).  6  968 patients with data available 
(group A = 513 patients; group B = 300 patients; group C = 155 patients).
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dle branch block was systematically more frequent in pa-
tients without AF. Cardiac enlargement (defined as car-
diothoracic ratio  1 0.55), data for which were available 
only in a small percentage of patients (12%), was seen to 
be associated with AF in all age groups.
 Pharmacological Treatment
 Table 2 reports the prescription patterns of the most 
relevant drugs for HF in each age group according to the 
presence of AF (mean prescription rate across the 5 years 
of the registry enrolment, i.e. 1995–1999). AF was associ-
ated with a lower use of both ACE inhibitors and   -block-
ers with increasing age. As expected, digoxin and warfa-
rin therapy were more frequently prescribed in patients 
with AF, although in patients over 75 years, oral antico-
agulant therapy was markedly underused. In contrast, 
the utilization of antiplatelets increased with age and in 
the absence of AF. Diuretics were systematically used 
more frequently in patients with AF than in those with-
out AF.
 One-Year Outcomes
 Univariate Analysis
 The results of univariate analysis of 1-year outcomes 
are reported in  table 3 . The all-cause mortality rate in-
creased with age both in patients with AF and in those 
without AF. In groups A and B, AF was statistically sig-
nificantly associated with a higher total mortality rate 
(13.0 vs. 8.5%, p = 0.0002, and 15.2 vs. 11.3%, p = 0.008, 
respectively) while it was not in the older patients (group 
C: 17.5 vs. 15.2%; p = 0.31). Sudden death was significant-
ly more frequent in patients with AF only in younger pa-
tients (group A: 6.3 vs. 3.7%; p = 0.002), whereas in older 
patients, we did not find any significant difference in the 
incidence of sudden death among patients with AF and 
those in sinus rhythm (group B: 4.9 vs. 5.4%, p = 0.62; 
group C: 5.3 vs. 4.9%, p = 0.75). Similarly, only younger 
patients with AF had significantly higher hospitalization 
rates (group A: 28.6 vs. 22.1%; p = 0.0002), while in the 2 
older groups of patients, no significant differences were 
detected among those with AF and those in sinus rhythm 
 Table 2.  Rates of drug prescriptions in the 3 groups of patients according to the presence or absence of AF
 Group A: age ≤65 years
 (n = 4,261) 
 Group B: age 65–75 years
 (n = 2,651) 
 Group C: age >75 years
 ( n = 1,266) 
 AF
 (n = 683) 
 no AF
 (n = 3,578) 
p  AF
 (n = 638) 
 no AF
 (n = 2,013) 
p  AF
 ( n = 412) 
 no AF
 (n = 854) 
p 
  -Blockers, %  18.3  25.3  <0.0001  11.1  17.0 0.001 5.3 8.1 0.07 
 ACE inhibitors, %  84.0  85.9 0.20  77.3  80.4 0.08  71.1  74.1 0.25 
 Digoxin, %  89.0  59.1  <0.0001  84.3  57.3  <0.0001  84.2  56.3  <0.0001 
 Oral anticoagulant, %  71.6  23.7  <0.0001  58.0  16.9  <0.0001  26.7 9.1  <0.0001 
 Aspirin, %  12.5  33.6  <0.0001  22.6  43.0  <0.0001  37.1  43.4 0.03 
 Other antiarrhythmics, % 1  29.0  24.4 0.011  24.5  25.7 0.52  19.9  22,6 0.28 
 Diuretics, %  91.5  78.3  <0.0001  92.2  84.6  <0.0001  89.8  84.5 0.011 
 1  T his includes the following drugs: antiarrhythmics class Ia-Ib-Ic, class III and class IV. 
 
 
 Table 3.  One-year outcomes in the 3 age groups according to the presence or absence of AF
 Group A: age ≤65 years
 (n = 4,261) 
 Group B: age 65–75 years
 (n = 2,651) 
 Group C: age >75 years
 ( n = 1,266) 
 AF
 (n = 683) 
 no AF
 (n = 3,578) 
 p  AF
 (n = 638) 
 no AF
 (n = 2013) 
 p  AF
 ( n = 412) 
 no AF
 (n = 854) 
 p 
 1-year all-cause mortality, %  13.0 8.5  0.0002  15.2  11.3  0.008  17.5  15.2  0.31 
 1-year sudden death, % 6.3 3.7  0.002 4.9 5.4  0.62 5.3 4.9  0.75 
 1-year hospitalization, %  28.6  22.1  0.0002  23.8  23.8  0.99  21.4  18.2  0.17 
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 Fig. 1. Kaplan-Meier curves of 1-year total mortality in the 3 age 
groups according to the presence or absence of AF.
 
 Fig. 2. Kaplan-Meier curves of 1-year sudden death in the 3 age 
groups according to the presence or absence of AF. 
 Baldasseroni et al. Cardiology 2010;116:79–8884
(group B: 23.8 vs. 23.8%, p = 0.99; group C: 21.4 vs. 18.2%, 
p = 0.17). Kaplan-Meier curves according to the presence/
absence of AF for 1-year all-cause death, sudden death 
and hospitalization are shown in  figures 1–3 .
 All-cause mortality curves were significantly different 
between patients with AF and those without AF in groups 
A and B (p = 0.0001 and p = 0.0084, respectively); sudden 
death and hospitalization curves diverged significantly 
between patients with AF and those without only in 
group A (p = 0.001 and p  ! 0.0001, respectively). In all 
other cases, the difference between the curves was not 
statistically significant.
 Multivariate Analysis
 In the models in which age was included as a continu-
ous variable, both AF and age were independent predic-
tors of all-cause mortality [hazard ratio (HR) 1.22, 95% 
confidence interval (CI) 1.04–1.42, and HR 1.03, 95% CI 
1.02–1.03, respectively]. With regard to sudden death, age 
still maintained its independent predictive value (HR 
1.02, 95% CI 1.01–1.03), while neither AF nor age were 
independent predictors of all-cause hospitalization.
 The results of the multivariate analyses with regard to 
1-year all-cause mortality, sudden death and hospitaliza-
tion in each age group are shown in  figure 4 . The presence 
of AF was an independent predictor of 1-year outcomes 
in younger patients (group A), whereas it predicted only 
1-year all-cause mortality in group B. In group C, AF was 
not confirmed to be an independent predictor of out-
come.
 Discussion
 General Considerations
 It is well known how AF negatively modifies the he-
modynamic and clinical profile of patients affected by 
HF  [7] . It seems reasonable to postulate that these nega-
tive effects may affect prognosis, particularly in the el-
derly, in whom the loss of atrial contribution greatly lim-
its cardiac reserve  [15] and predisposes to thromboembo-
lism  [19] . The incidence and prevalence of AF increases 
with age and worsening HF  [12, 20] , and our data also 
confirm the elevated prevalence of AF in patients of ad-
vanced age and NYHA class. In all 3 groups of our study 
population, the presence of AF in patients with HF was 
strongly associated with previous hospitalizations, rein-
forcing the relationship between AF and a worse clinical 
profile of HF. With increasing age, AF is more frequently 
detected in females (in patients aged less than or equal to 
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 Fig. 3. Kaplan-Meier curves of 1-year hospitalization in the 3 age 
groups according to the presence or absence of AF.
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65 years, females were prevalent among those without 
AF) and also in patients with preserved left ventricular 
ejection fraction  [21] . Ischemic and hypertensive etiology 
were the main causes of HF in our older group, both in 
patients with and without AF, as previously reported in 
the Framingham Heart Study  [4] .
 Analyzing our data concerning electrolyte distur-
bances, we found that patients affected by AF presented 
lower levels of serum potassium compared to those in si-
nus rhythm, but these differences were statistically sig-
nificant only in the older group; this finding could be 
explained by the fact that an aged kidney is more prone 
to potassium dispersion during diuretic therapy  [22] . In-
terestingly, renal insufficiency, defined as serum creati-
nine  1 2.5 mg/dl, was observed at a higher rate in patients 
without AF in all 3 age groups, and the difference was 
significant in group C. We might hypothesize that the 
presence of renal insufficiency, with its tendency to hy-
perkalemia, might be protective against developing a hy-
pokalemic state, which is known to be a risk factor for the 
onset of AF as well as for other cardiac arrhythmias  [23] .
 Pharmacological Approach
 First of all, we must underline the general underuse of 
  -blockers in our study population; this clinical approach 
is most evident in the older group with AF. This finding is 
in accordance with data derived from another Italian reg-
istry  [24] , demonstrating the substantial difference in the 
utilization of   -blockers between randomized trials  [25, 
26] and routine clinical practice, particularly in elderly pa-
tients, even though the efficacy of   -blockers in older pa-
tients with HF has been confirmed  [27] . However, we must 
underline that this finding is probably justified on the ba-
sis of two significant considerations. Firstly, it represents 
the mean prescription rate of this drug over a long period 
of enrolment, as the registry started in 1995, and secondly, 
the first large clinical trial which tested the efficacy of   -
blockers was the US carvedilol trial  [26] , published in 1996, 
and it is known that the transfer of evidence derived from 
randomized clinical trials is a process that usually takes 
several years. The underuse of   -blockers in the 3 age 
groups with AF in the present study was probably also re-
lated to the high rate of prescription of digoxin; in fact, this 
drug was prescribed in all 3 groups of AF patients at a sig-
nificantly higher rate than in those patients in sinus 
rhythm. ACE inhibitors were prescribed at a high rate in 
all groups, with an overall rate of more than 80%, in ac-
cordance with the results of the Study of Patients Intoler-
ant of Converting Enzyme Inhibitors registry  [28] .
 There are clear indications that patients with AF 
should be treated with oral anticoagulation therapy in the 
presence of one or more other risk factors for systemic 
embolism and in the absence of hemorrhage risk  [29] . 
Our data demonstrate that a deep-seated caution exists 
also in the cardiology care setting, particularly in regard 
to the elderly, in whom the greatest benefit has already 
been documented  [29] .
 Prognostic Implications
 The prognostic role of AF in patients affected by HF 
has been debated for a long time, with controversial find-
ings  [12] . Two large trials  [30, 31] with a total of 14,000 
patients reported that the all-cause mortality rate was sig-
nificantly higher in the presence of AF. Middlekauff et al. 
 [32] demonstrated the negative prognostic role of AF in 
patients with HF, even though, interestingly, in this study 
the authors underlined that AF lost its predictive power 
in patients with a worse hemodynamic profile. In the Vet-
erans Affairs Vasodilator-Heart Failure Trial, AF was not 
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 Fig. 4. Independent prognostic value of AF in the 3 groups of pa-
tients. Multivariate Cox regression models adjusted for gender, 
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rate, previous hospitalization for HF, creatinine ( 1 2.5 mg/dl), car-
diothoracic ratio ( 1 0.55), ejection fraction ( ^  30%), third heart 
sound, ventricular arrhythmias,   -blockers and ACE inhibitor 
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found to be a negative predictive variable in patients with 
AF and NYHA class II–III  [33] , and Crijns et al. [34] , in 
patients with more advanced NYHA class (III–IV), dem-
onstrated that there was no significant difference in the 
mortality rate after adjustment for age and for clinical 
and hemodynamic variables. More recently, data derived 
from the Valsartan Heart Failure Trial  [20] showed that 
the occurrence of AF in patients with chronic HF inde-
pendently increases the risk of all-cause mortality and 
combined mortality and morbidity by 40 and 38%, re-
spectively. Regarding this controversy, data available in 
the literature seem to underline how the clinical rele-
vance of AF could change depending on the different lev-
els of cardiac dysfunction and clinical impairment of the 
patients  [9] .
 Our data can contribute to defining the prognostic 
role of AF according to the age of the patients. In a cohort 
of outpatients followed by cardiologists, we observed that 
AF maintains its independent effect on 1-year all-cause 
mortality in those aged less than or equal to 75 years ir-
respective of left ventricular systolic function, confirm-
ing the results of Mamas et al.  [35] and the ancillary anal-
ysis of the Candesartan in Heart Failure-Assessment of 
Reduction in Mortality and Morbidity study  [36] . In our 
study, in the youngest subgroup of patients, the Kaplan-
Meier curves diverged very early during the follow-up pe-
riod; this finding could have important clinical conse-
quences, suggesting a possible prognostic benefit of a 
timely aggressive approach to maintain or restore sinus 
rhythm in this young population of patients.
 Our sample is different from the study population an-
alyzed by Aronow et al.  [37] ; these authors found a sig-
nificant association between AF and mortality in very old 
patients regardless of the presence of systolic dysfunc-
tion. In that study, the mean age of the population was 
over 80 years, all patients had a prior myocardial infarc-
tion and finally the differences in mortality rate between 
patients with AF and those without were related primar-
ily to preserved systolic function  [37] .
 The fact that AF is not an independent predictor for 
mortality and hospitalization in the oldest patients is an 
important finding but, in our opinion, is not sufficient to 
influence therapeutic choices in the very elderly popula-
tion, because other relevant outcomes should be consid-
ered, such as the risk of disabling stroke, global function-
al impairment and the health-related quality of life  [38] . 
So, in this aged population, therapeutic decisions must be 
individualized from a geriatric point of view.
 Some limitations of our study must be acknowledged. 
ECG analysis and diagnosis of AF were not carried out in 
a single core laboratory using standardized, blinded 
methods and quality control techniques; the diagnosis 
was defined by each cardiologist on the basis of clinical 
history and ECG at entry into the registry. Further, no 
data are available regarding the duration of the electrical 
disturbance at the time of enrolment in the registry.
 Finally, we must underline that our data are derived 
from outpatients managed in a cardiology ward. For this 
reason, these patients presented a low level of comorbid-
ity compared to those usually treated in internal and ge-
riatric medicine wards. Therefore, our results are surely 
not fully generalizable to all patients with AF and HF.
 Conclusion
 We found that the prevalence of AF increased with age 
and was associated with a worse clinical profile and a 
higher mortality rate. However, AF was able to predict all-
cause mortality only in patients aged  ^  75 years irrespec-
tive of left ventricular systolic function. Sudden death and 
all-cause hospitalization rates were predicted by the pres-
ence of AF only in the youngest group of patients.
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